Identification of risk factors for bronchiolitis obliterans syndrome after reduced toxicity conditioning before hematopoietic cell transplantation

Bone Marrow Transplantation

Volumn 48, Issue 8, 2013, Pages 1098-1103

  Duque Afonso, J ^a,b   Ihorst, G ^a   Wasch R ^a   Bertz, H ^a   Muller Quernheim J ^a   Finke, J ^a   Prasse, A ^a   Marks, R ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b STANFORD UNIVERSITY   (United States)

Author keywords

Allogeneic hematopoietic cell transplantation; Bronchiolitis obliterans; Reduced conditioning protocol

Indexed keywords

ALEMTUZUMAB; CARMUSTINE; CYCLOSPORIN A; FLUDARABINE; MELPHALAN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THYMOCYTE ANTIBODY;

ADULT; AGE; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; ASTHMA; BACTERIAL PNEUMONIA; BRONCHIOLITIS OBLITERANS; BRONCHITIS; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DIFFUSING CAPACITY OF THE LUNG FOR CARBON MONOXIDE; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HUMAN; LUNG ASPERGILLOSIS; LUNG DIFFUSION CAPACITY; LUNG DISEASE; LUNG MYCOSIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; SIDE EFFECT; SMOKING; T CELL DEPLETION; UPPER RESPIRATORY TRACT INFECTION; VIRAL RESPIRATORY TRACT INFECTION;

ADULT; AGE FACTORS; AGED; BRONCHIOLITIS OBLITERANS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INCIDENCE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 84881370294     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2013.3     Document Type: Article

References (34)

1. Marks R, Potthoff K, Hahn J, Ihorst G, Bertz H, Spyridonidis A et al. Reduced-Toxicity conditioning with fludarabine, BCNU, and melphalan in allogeneic hematopoietic cell transplantation: Particular activity against advanced hematologic malignancies. Blood 2008; 112: 415-425
2. Deschler B, Binek K, Ihorst G, Marks R, Wäsch R, Bertz H et al. Prognostic factor and quality of life analysis in 160 patients aged 4or-60 years with hematologic neoplasias treated with allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2010; 16: 967-975
3. Sakaida E, Nakaseko C, Harima A, Yokota A, Cho R, Saito Y et al. Late-onset noninfectious pulmonary complications after allogeneic stem cell transplantation are significantly associated with chronic graft-versus-host disease and with the graft-versus-leukemia effect. Blood 2003; 102: 4236-4242
4. Palmas A, Tefferi A, Myers JL, Scott JP, Swensen SJ, Chen MG et al. Late-onset noninfectious pulmonary complications after allogeneic bone marrow transplantation. Br J Haematol 1998; 100: 680-687
5. Afessa B, Litzow MR, Tefferi A. Bronchiolitis obliterans and other late onset noninfectious pulmonary complications in hematopoietic stem cell transplantation. Bone Marrow Transplant 2001; 28: 425-434
6. Yoshihara S, Yanik G, Cooke KR, Mineishi S. Bronchiolitis obliterans syndrome (BOS), bronchiolitis obliterans organizing pneumonia (BOOP), and other lateonset noninfectious pulmonary complications following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2007; 13: 749-759
7. Yousem SA. The histological spectrum of pulmonary graft-versus-host disease in bone marrow transplant recipients. Hum Pathol 1995; 26: 668-675
8. Filipovich AH, Weisdorf D, Pavletic S, Socié G, Wingard JR, Lee SJ et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945-956
9. Williams KM, Chien JW, Gladwin MT, Pavletic SZ. Bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation. JAMA 2009; 302: 306-314
10. Patriarca F, Skert C, Sperotto A, Damiani D, Cerno M, Geromin A et al. Incidence, outcome, and risk factors of late-onset noninfectious pulmonary complications after unrelated donor stem cell transplantation. Bone Marrow Transplant 2004; 33: 751-758
11. Patriarca F, Skert C, Bonifazi F, Sperotto A, Fili C, Stanzani M et al. Effect on survival of the development of late-onset non-infectious pulmonary complications after stem cell transplantation. Haematologica 2006; 91: 1268-1272
12. Yoshihara S, Tateishi U, Ando T, Kunitoh H, Suyama H, Onishi Y et al. Lower incidence of bronchiolitis obliterans in allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning compared with myeloablative conditioning. Bone Marrow Transplant 2005; 35: 1195-1200
13. Finke J, Bethge WA, Schmoor C, Ottinger HD, Stelljes M, Zander AR et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in hematopoietic cell transplantation from matched unrelated donors: A randomised, open-label, multicentre phase 3 trial. Lancet Oncol 2009; 10: 855-864
14. Bertz H, Spyridonidis A, Wäsch R, Grüllich C, Egger M, Finke J. A novel GVHDprophylaxis with low-dose alemtuzumab in allogeneic sibling or unrelated donor hematopoetic cell transplantation: The feasibility of deescalation. Biol Blood Marrow Transplant 2009; 15: 1563-1570
15. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15: 825-828
16. Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE et al. Chronic graft-versus-host syndrome in man. A long-Term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204-217
17. American Thoracic Society. Single-breath carbon monoxide diffusing capacity (transfer factor). Recommendations for a standard technique, 1995 update. Am J Respir Crit Care Med 1995; 152: 2185-2198
18. American Thoracic Society. Standardization of spirometry, 1994 Update. Am J Respir Crit Care Med 1995; 152: 1107-1136
19. Stocks J, Quanjer PH. Reference values for residual volume, functional residual capacity and total lung capacity. ATS workshop on lung volume measurements. Official statement of The European Respiratory Society. Eur Respir J 1995; 8: 492-506
20. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: New representations of old estimators. Stat Med 1999; 18: 695-706
21. Fine J, Gray. R. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94: 496-509
22. Dignam JJ, Kocherginsky MN. Choice and interpretation of statistical tests used when competing risks are present. J Clin Oncol 2008; 26: 4027-4034
23. Cao TM, Negrin RS, Stockerl-Goldstein KE, Johnston LJ, Shizuru JA, Taylor TL et al. Pulmonary toxicity syndrome in breast cancer patients undergoing BCNU-containing high-dose chemotherapy and autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant 2000; 6: 387-394
24. Chien JW, Martin PJ, Gooley TA, Flowers ME, Heckbert SR, Nichols WG et al. Airflow obstruction after myeloablative allogeneic hematopoietic stem cell transplantation. Am J Respir Crit Care Med 2003; 168: 208-214
25. Erard V, Chien JW, Kim HW, Nichols WG, Flowers ME, Martin PJ et al. Airflow decline after myeloablative allogeneic hematopoietic cell transplantation: The role of community respiratory viruses. J Infect Dis 2006; 193: 1619-1625
26. Vogelsang GB. How I treat chronic graft-versus host disease. Blood 2001; 97: 1196-1201
27. Milano F, Au MA, Boeckh MJ, Deeg HJ, Chien JW. Evaluating the impact of antithymocyte globulin on lung function at 1 year after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2011; 17: 703-709
28. Pavletic SZ, Carter SL, Kernan NA, Henslee-Downey J, Mendizabal AM, Papadopoulos E et al. Influence of T-cell depletion on chronic graft-versus-host disease: Results of a multicenter randomized trial in unrelated marrow donor transplantation. Blood 2005; 106: 3308-3313
29. Ditschkowski M, Elmaagacli AH, Trenschel R, Peceny R, Koldehoff M, Schulte C et al. T-cell depletion prevents from bronchiolitis obliterans and bronchiolitis obliterans with organizing pneumonia after allogeneic hematopoietic stem cell transplantation with related donors. Haematologica 2007; 92: 558-561
30. Bacigalupo A, Lamparelli T, Barisione G, Bruzzi P, Guidi S, Alessandrino PE et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: Long-Term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biol Blood Marrow Transplant 2006; 12: 560-565
31. Socié G, Schmoor C, Bethge WA, Ottinger HD, Stelljes M, Zander AR et al. Chronic graft-versus-host disease: Long-Term results from a randomized trial on graftversus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. Blood 2011; 117: 6375-6382
32. Freudenberger TD, Madtes DK, Curtis JR, Cummings P, Storer BE, Hackman RC. Association between acute and chronic graft-versus-host disease and bronchiolitis obliterans organizing pneumonia in recipients of hematopoietic stem cell transplants. Blood 2003; 102: 3822-3828
33. Santo Tomas LH, Loberiza Jr. FR, Klein JP, Layde PM, Lipchik RJ, Rizzo JD et al. Risk factors for bronchiolitis obliterans in allogeneic hematopoietic stem-cell transplantation for leukemia. Chest 2005; 128: 153-161
34. Hildebrandt GC, Fazekas T, Lawitschka A, Bertz H, Greinix H, Halter J et al. Diagnosis and treatment of pulmonary chronic GVHD: Report from the consensus conference on clinical practice in chronic GVHD. Bone Marrow Transplant 2011; 46: 1283-1295